PCSK9 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR ALCOHOLIC LIVER DISEASE

被引：0
|
作者：
Lee, J. [1 ]
Mukhopadhyay, P. [1 ]
Matyas, C. [1 ]
Trojnar, E. [1 ]
Paloczi, J. [1 ]
Yang, Y. R. [1 ]
Blank, B. A. [1 ]
Savage, C. [1 ]
Sorokin, A. V. [1 ]
Mehta, N. N. [1 ]
Vendruscolo, J. C. M. [1 ]
Koob, G. F. [1 ]
Vendruscolo, L. F. [1 ]
Pacher, P. [1 ]
Lohoff, F. W. [1 ]
机构：
[1] NIAAA, Sect Clin Genom & Expt Therapeut, NIH, Bethesda, MD USA
来源：
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH | 2020年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
151
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [1] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Lee, Ji Soo
    Mukhopadhyay, Partha
    Matyas, Csaba
    Trojnar, Eszter
    Paloczi, Janos
    Yang, Yuan Ru
    Blank, Brandon A.
    Savage, Cody
    Sorokin, Alexander V.
    Mehta, Nehal N.
    Vendruscolo, Janaina C. M.
    Koob, George F.
    Vendruscolo, Leandro F.
    Pacher, Pal
    Lohoff, Falk W.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Ji Soo Lee
    Partha Mukhopadhyay
    Csaba Matyas
    Eszter Trojnar
    Janos Paloczi
    Yuan Ru Yang
    Brandon A. Blank
    Cody Savage
    Alexander V. Sorokin
    Nehal N. Mehta
    Janaina C. M. Vendruscolo
    George F. Koob
    Leandro F. Vendruscolo
    Pal Pacher
    Falk W. Lohoff
    Scientific Reports, 9
  • [3] PCSK9 as a therapeutic target for cardiovascular disease
    Zhang, Pei-Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 810 - 814
  • [4] Inhibition of hepatic PCSK9 as a novel therapeutic target ameliorates metabolic steatohepatitis in mice
    Mijiti, Tuoluonayi
    Chen, Xiaocui
    Ma, Xiang
    Ma, Yitong
    Ma, Xiumin
    Chen, Bangdang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [5] PCSK9 as a Therapeutic Target in Atherosclerosis
    Ali J. Marian
    Current Atherosclerosis Reports, 2010, 12 (3) : 151 - 154
  • [6] PCSK9 as a therapeutic target of dyslipidemia
    Seidah, Nabil G.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (01) : 19 - 28
  • [7] The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
    Theocharidou, Eleni
    Papademetriou, Marianna
    Reklou, Andromachi
    Sachinidis, Alexandros
    Boutari, Chrisoula
    Giouleme, Olga
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3654 - 3657
  • [8] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
    Momtazi-Borojeni, Amir Abbas
    Banach, Maciej
    Ruscica, Massimiliano
    Sahebkar, Amirhossein
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208
  • [9] PCSK9 and the Liver-Brain Axis: A Novel Therapeutic Target for Alcohol Use Disorder
    Lee, Jisoo
    Mukhopadhyay, Partha
    Matyas, Csaba
    Trojnar, Eszter
    Paloczi, Janos
    Rosoff, Dan
    Yang, Yuan Ru
    Blank, Brandon
    Savage, Cody
    Vendruscolo, Janaina
    Koob, George
    Vendruscolo, Leandro
    Pacher, Pal
    Lohoff, Falk
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 530 - 530
  • [10] PCSK9:: a promising therapeutic target for dyslipidemias?
    Lambert, G
    Krempf, M
    Costet, P
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2006, 17 (03): : 79 - 81
12345